Cancer modelling in the NGS era - Part I: Emerging technology and initial modelling

Critical Reviews in Oncology/Hematology

Volumn 96, Issue 2, 2015, Pages 274-307

  Rovigatti, Ugo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

ALK+NSCLC; Cancer modelling history; Chronic myelogenous leukaemia (CML); Crizotinib; Cytoxic chemotherapy; Erlotinib; Gefitinib; Gene networks; IDH mutations; Imatinib; Inter tumour heterogeneity; Intra tumour heterogeneity; Ion torrent; Melanoma; Nanopore; Next generation sequencing (NGS); Non small cell lung carcinoma (NSCLC); Targeted gene therapy (TGT); Tumour clonality; Vemurafenib

Indexed keywords

AFATINIB; ALECTINIB; B RAF KINASE; B RAF KINASE INHIBITOR; DRAMETINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; IMATINIB; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; TRAMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; BRAF GENE; BRAIN TUMOR; CANCER ADJUVANT THERAPY; CANCER MODEL; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STEM CELL; CANCER SUSCEPTIBILITY; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLONAL OUTGROWTH CANCER MODEL; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; CYTOGENETICS; DANAHER MOTION POLONATOR SEQUENCING; DNA SEQUENCE; DRUG RESEARCH; GENE; GENE ACTIVITY; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE MUTATION; GENE NETWORK CANCER MODEL; GENE REARRANGEMENT; GENE TARGETING; GENE TECHNOLOGY; GENE THERAPY; GENETIC STABILITY; GENETIC SUSCEPTIBILITY; GENOME ANALYSIS; HIGH THROUGHPUT SEQUENCING; HUMAN GENOME PROJECT; INTELLIGENT BIO SYSTEMS SEQUENCING; INTERMETHOD COMPARISON; INTERTUMOR HETEROGENEITY; INTRATUMOR HETEROGENEITY; ION TORRENT TECHNOLOGY; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; MELANOMA; METABOLIC REGULATION; MOLECULAR EVOLUTION; MOLECULARLY TARGETED THERAPY; NANOPORE SEQUENCING TECHNOLOGY; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; ONCOGENE RAS; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; PHILADELPHIA 1 CHROMOSOME; PROCESS OPTIMIZATION; PROGRESSION FREE SURVIVAL; REVIEW; RNA SEQUENCE; SANGER SEQUENCING; SEQUENCING TECHNOLOGY; SINGLE MOLECULE DNA SEQUENCING; SINGLE MOLECULE REAL TIME SEQUENCING; TREATMENT RESPONSE; WHOLE GENOME SEQUENCING; HIGH THROUGHPUT SCREENING; HISTORY; HUMAN; NEOPLASM; PROCEDURES;

HIGH-THROUGHPUT SCREENING ASSAYS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; NEOPLASMS;

EID: 84955202845     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.05.017     Document Type: Review

References (322)

1. Collins F.S., Barker A.D. Mapping the cancer genome. Pinpointing the genes involved in cancer will help chart a new course across the complex landscape of humamalignancies. Sci Am 2007, 296(3):50-57.
2. Mardis E.R., Wilson R.K. Cancer genome sequencing: a review. Hum Mol Genet 2009, 18(R2):R163-R168.
3. Consortium T.-T.I.C.G. International network of cancer genome projects. Nature 2010, 464(7291):993-998.
4. Ding L. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455:1069-1075.
5. Jones S. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806.
6. Fisher R., Larkin J., Swanton C. Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity. EPMA J 2012, 3(1):1.
7. Yap T., Swanton C., de Bono J. Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon?. EPMA J 2012, 3(1):3.
8. Meyerson M., Gabriel S., Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet 2010, 11(10):685-696.
9. Timmermann B., Kerick M., Roehr C., Fischer A., Isau M., Boerno S.T., et al. Somatic mutation profiles of MSI and MSS colorectal cancer identified by whole exome next generation sequencing and bioinformatics analysis. PLoS ONE 2010, 5(12):e15661.
10. Kostic A.D., Ojesina A.L., Pedamallu C.S., Jung J., Verhaak R.G.W., Getz G., et al. PathSeq: software to identify or discover microbes by deep sequencing of human tissue. Nat Biotechnol 2011, 29(5):393-396.
11. Morey M., Fernández-Marmiesse A., Castiñeiras D., Fraga J.M., Couce M.L., Cocho J.A. A glimpse into past, present, and future DNA sequencing. Mol Genet Metab 2013, 110(1-2):3-24.
12. Hudson T., Anderson W., Artez A., Barker A., Bell C., Bernabé R., et al. International network of cancer genome projects. Nature 2010, 464(7291):993-998.
13. Stratton M. Exploring the genomes of cancer cells: progress and promise. Science 2011, 331(6024):1553-1558.
14. Zhang J., Baran J., Cros A., Guberman J.M., Haider S., Hsu J., et al. International Cancer Genome Consortium Data Portal - a one-stop shop for cancer genomics data. Database 2011.
15. Network TCGAR, Weinstein J.N., Collisson E.A., Mills G.B., Shaw K.R.M., Ozenberger B.A., et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nature 2013, 45(10):1113-1120.
16. Merlo L.M.F., Maley C.C. The role of genetic diversity in cancer. J Clin Invest 2010, 120(2):401-403.
17. Navin N. Tumour evolution inferred by single-cell sequencing. Nature 2011, 472:90-94.
18. Greaves M., Maley C.C. Clonal evolution in cancer. Nature 2012, 481(7381):306-313.
19. Marusyk A., Almendro V., Polyak K. Intra-tumour heterogeneity: a looking glass for cancer?. Nat Rev Cancer 2012, 12(5):323-334.
20. Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res 2012, 72(19):4875-4882.
21. Eifert C., Powers R.S. From cancer genomes to oncogenic drivers, tumour dependencies and therapeutic targets. Nat Rev Cancer 2012, 12(8):572-578.
22. Gillies R.J., Verduzco D., Gatenby R.A. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer 2012, 12(7):487-493.
23. Aktipis C.A., Boddy A.M., Gatenby R.A., Brown J.S., Maley C.C. Life history trade-offs in cancer evolution. Nat Rev Cancer 2013, 13(12):883-892.
24. Burrell R.A., McGranahan N., Bartek J., Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013, 501(7467):338-345.
25. Burrell R.A., Swanton C. The evolution of the unstable cancer genome. Curr Opin Genet Dev 2014, 24(0):61-67.
26. Kreso A., Dick J.E. Evolution of the cancer stem cell model. Cell Stem Cell 2014, 14(3):275-291.
27. Marshall E. Genome sequencing. Clinton and Blair back rapid release of data. Science 2000, 287(5460):1903.
28. Lander E.S. Nature 2001, 409(6822):860.
29. Venter J.C. Science 2001, 291(5507):1304.
30. Collins F.S., Green E.D., Guttmacher A.E., Guyer M.S. A vision for the future of genomics research. Nature 2003, 422(6934):835-847.
31. Collins F.S., Morgan M., Patrinos A. The human genome project: lessons from large-scale biology. Science 2003, 300(5617):286-290.
32. Ansorge W., Sproat B.S., Stegemann J., Schwager C. A non-radioactive automated method for DNA sequence determination. J Biochem Biophys Methods 1986, 13(6):315-323.
33. Ansorge W., Sproat B., Stegemann J., Schwager C., Zenke M. Automated DNA sequencing: ultrasensitive detection of fluorescent bands during electrophoresis. Nucleic Acids Res 1987, 15(11):4593-4602.
34. Pareek C., Smoczynski R., Tretyn A. Sequencing technologies and genome sequencing. J Appl Genet 2011, 52:413-435.
35. Niedringhaus T.P., Milanova D., Kerby M.B., Snyder M.P., Barron A.E. Landscape of next-generation sequencing technologies. Anal Chem 2011, 83(12):4327-4341.
36. Ozsolak F. Third-generation sequencing techniques and applications to drug discovery. Expert Opin Drug Discov 2012, 7(3):231-243.
37. NHGRI, N.H.G.R.I., 2014, NHGRI. http://www.genome.gov/sequencingcosts.
38. Church G.M. Genomes for all. Sci Am 2006, 294(1):46-54.
39. Service R.F. The race for the $1000 genome. Science 2006, 311(5767):1544-1546.
40. Metzker M.L. Emerging technologies in DNA sequencing. Genome Res 2005, 15(12):1767-1776.
41. Meyerson M., Gabriel S., Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet 2010, 11:685-696.
42. Metzker M.L. Sequencing technologies-the next generation. Nat Rev Genet 2010, 11(1):31-46.
43. Mardis E.R. Next-generation DNA sequencing methods. Annu Rev Genomics Hum Genet 2008, 9(1):387-402.
44. Ronaghi M., Uhlén M.P., Nyrén l. A sequencing method based on real-time pyrophosphate. Science 1998, 281(5375):363-365.
45. Fuller C.W., Middendorf L.R., Benner S.A., Church G.M., Harris T., Huang X., et al. The challenges of sequencing by synthesis. Nat Biotechnol 2009, 27(11):1013-1023.
46. Mitra R.D., Shendure J., Olejnik J., Edyta-Krzymanska-Olejnik, Church G.M. Fluorescent in situ sequencing on polymerase colonies. Anal Biochem 2003, 320(1):55-65.
47. AB, L.T.-, 2014, Life Technologie. https://products.appliedbiosystems.com/ab/en/US/adirect/ab.
48. Margulies M., Egholm M., Altman W.E., Attiya S., Bader J.S., Bemben L.A., et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature 2005, 437(7057):376-380.
49. Perkel J.M. Life science technologies: Sanger who?. Seq Next Gener Sci 2009, 324(5924):275-279.
50. Ku C.-S., Roukos D.H. From next-generation sequencing to nanopore sequencing technology: paving the way to personalized genomic medicine. Expert Rev Med Dev 2013, 10(1):1-6.
51. Braslavsky I., Hebert B., Kartalov E., Quake S.R. Sequence information can be obtained from single DNA molecules. Proc Natl Acad Sci U S A 2003, 100:3960-3964.
52. Harris T.D., Buzby P.R., Babcock H., Beer E., Bowers J., Braslavsky I., et al. Single-molecule DNA sequencing of a viral genome. Science 2008, 320(5872):106-109.
53. Ozsolak F., Kapranov P., Foissac S., Kim S.W., Fishilevich E., Monaghan A.P., et al. Comprehensive polyadenylation site maps in yeast and human reveal pervasive alternative polyadenylation. Cell 2010, 143(6):1018-1029.
54. Ozsolak F., Platt A.R., Jones D.R., Reifenberger J.G., Sass L.E., McInerney P., et al. Direct RNA sequencing. Nature 2009, 461(7265):814-818.
55. Donis-Keller H., Maxam A.M., Gilbert W. Mapping adenines, guanines, and pyrimidines in RNA. Nucleic Acids Res 1977, 4(8):2527-2538.
56. Ozsolak F., Milos P.M. RNA sequencing: advances, challenges and opportunities. Nat Rev Genet 2011, 12(2):87-98.
57. Levene M.J., Korlach J., Turner S.W., Foquet M., Craighead H.G., Webb W.W. Zero-mode waveguides for single-molecule analysis at high concentrations. Science 2003, 299(5607):682-686.
58. Foquet M., Samiee K.T., Kong X., Chauduri B.P., Lundquist P.M., Turner S.W., et al. Improved fabrication of zero-mode waveguides for single-molecule detection. J Appl Phys 2008, 103(3). 10.1063/1.2831366.
59. Schadt E.E., Turner S., Kasarskis A. A window into third-generation sequencing. Hum Mol Genet 2010, 19(R2):R227-R240.
60. Korlach J., Marks P.J., Cicero R.L., Gray J.J., Murphy D.L., Roitman D.B., et al. Selective aluminum passivation for targeted immobilization of single DNA polymerase molecules in zero-mode waveguide nanostructures. Proc Natl Acad Sci U S A 2008, 105(4):1176-1181.
61. Eid J., Fehr A., Gray J., Luong K., Lyle J., Otto G., et al. Real-time DNA sequencing from single polymerase molecules. Science 2009, 323(5910):133-138.
62. Chin C.-S., Sorenson J., Harris J.B., Robins W.P., Charles R.C., Jean-Charles R.R., et al. The origin of the Haitian cholera outbreak strain. N Engl J Med 2011, 364(1):33-42.
63. Rasko D.A., Webster D.R., Sahl J.W., Bashir A., Boisen N., Scheutz F., et al. Origins of the E. coli strain causing an outbreak of hemolytic-uremic syndrome in Germany. N Engl J Med 2011, 365(8):709-717.
64. Uemura S., Aitken C.E., Korlach J., Flusberg B.A., Turner S.W., Puglisi J.D. Real-time tRNA transit on single translating ribosomes at codon resolution. Nature 2010, 464(7291):1012-1017.
65. Leamon J.H., Lee W.L., Tartaro K.R., Lanza J.R., Sarkis G.J., deWinter A.D., et al. A massively parallel PicoTiterPlate-based platform for discrete picoliter-scale polymerase chain reactions. Electrophoresis 2003, 24(21):3769-3777.
66. Green R.E., Krause J., Ptak S.E., Briggs A.W., Ronan M.T., Simons J.F., et al. Analysis of one million base pairs of Neanderthal DNA. Nature 2006, 444(7117):330-336.
67. Leamon J.H., Rothberg J.M. Cramming more sequencing reactions onto microreactor chips. Chem Rev 2007, 107(8):3367-3376.
68. Wheeler D.A., Srinivasan M., Egholm M., Shen Y., Chen L., McGuire A., et al. The complete genome of an individual by massively parallel DNA sequencing. Nature 2008, 452(7189):872-876.
69. Rothberg J.M., Leamon J.H. The development and impact of 454 sequencing. Nat Biotechnol 2008, 26(10):1117-1124.
70. Merriman B.I.T.R., Team D., Rothberg J.M. Progress in ion torrent semiconductor chip based sequencing. Electrophoresis 2012, 33(23):3397-3417.
71. Rothberg J.M., Hinz W., Rearick T.M., Schultz J., Mileski W., Davey M., et al. An integrated semiconductor device enabling non-optical genome sequencing. Nature 2011, 475(7356):348-352.
72. Mellmann A., Harmsen D., Cummings C.A., Zentz E.B., Leopold S.R., Rico A., et al. Prospective genomic characterization of the German enterohemorrhagic Escherichia coli O104:H4 outbreak by rapid next generation sequencing technology. PLoS ONE 2011, 6(7). e22751.
73. Pennisi E. Semiconductors inspire new sequencing technologies. Science 2010, 327(5970):1190.
74. Gewin V. Nature 2011, 470:131. 10.1038/nj7332-131a.
75. Wanunu M. Nanopores: a journey towards DNA sequencing. Phys Life Rev 2012, 9(2):125-158.
76. Branton D., Deamer D.W., Marziali A., Bayley H., Benner S.A., Butler T., et al. The potential and challenges of nanopore sequencing. Nat Biotechnol 2008, 26(10):1146-1153.
77. Bayley H. Sequencing single molecules of DNA. Curr Opin Chem Biol 2006, 10(6):628-637.
78. Kasianowicz J.J., Brandin E., Branton D., Deamer D.W. Characterization of individual polynucleotide molecules using a membrane channel. Proc Natl Acad Sci U S A 1996, 93(24):13770-13773.
79. Gu L.-Q., Braha O., Conlan S., Cheley S., Bayley H. Stochastic sensing of organic analytes by a pore-forming protein containing a molecular adapter. Nature 1999, 398(6729):686-690.
80. Bayley H., Cremer P.S. Stochastic sensors inspired by biology. Nature 2001, 413(6852):226-230.
81. Ashkenasy N., Sánchez-Quesada J., Bayley H., Ghadiri M.R. Recognizing a single base in an individual DNA strand: a step toward DNA sequencing in nanopores. Angew Chem Int Ed 2005, 44(9):1401-1404.
82. Wu H.-C., Astier Y., Maglia G., Mikhailova E., Bayley H. Protein nanopores with covalently attached molecular adapters. J Am Chem Soc 2007, 129(51):16142-16148.
83. Sanderson K. Personal genomes: standard and pores. Nature 2008, 456(7218):23-25.
84. Bayley H. Interview: enriching the pore. Nanomedicine 2012, 7(6):807-810.
85. Astier Y., Braha O., Bayley H. Toward single molecule DNA sequencing: direct identification of ribonucleoside and deoxyribonucleoside 5'-monophosphates by using an engineered protein nanopore equipped with a molecular adapter. J Am Chem Soc 2006, 128(5):1705-1710.
86. Clarke J., Wu H.-C., Jayasinghe L., Patel A., Reid S., Bayley H. Continuous base identification for single-molecule nanopore DNA sequencing. Nat Nanotechnol 2009, 4(4):265-270.
87. Lieberman K.R., Cherf G.M., Doody M.J., Olasagasti F., Kolodji Y., Akeson M. Processive replication of single DNA molecules in a nanopore catalyzed by phi29 DNA polymerase. J Am Chem Soc 2010, 132(50):17961-17972.
88. Maglia G., Restrepo M.R., Mikhailova E., Bayley H. Enhanced translocation of single DNA molecules through α-hemolysin nanopores by manipulation of internal charge. Proc Natl Acad Sci U S A 2008, 105(50):19720-19725.
89. Butler T.Z., Pavlenok M., Derrington I.M., Niederweis M., Gundlach J.H. Single-molecule DNA detection with an engineered MspA protein nanopore. Proc Natl Acad Sci U S A 2008, 105(52):20647-20652.
90. Hayden E.C. Data from pocket-sized genome sequencer unveiled, NEWS Sharing. Nature 2014, http://www.nature.com/news/data-from-pocket-sized-genome-sequencer-unveiled-1.14724.
91. Hayden E.C. Nanopore genome sequencer makes its debut, NEWS Sharing. Nature 2012, http://www.nature.com/news/nanopore-genome-sequencer-makes-its-debut-1.10051.
92. Stoddart D., Heron A.J., Klingelhoefer J., Mikhailova E., Maglia G., Bayley H. Nucleobase recognition in ssDNA at the central constriction of the α-hemolysin pore. Nano Lett 2010, 10(9):3633-3637.
93. Manrao E.A., Derrington I.M., Pavlenok M., Niederweis M., Gundlach J.H. Nucleotide discrimination with DNA immobilized in the MspA nanopore. PLoS ONE 2011, 6(10). e25723.
94. Garaj S., Hubbard W., Reina A., Kong J., Branton D., Golovchenko J.A. Graphene as a subnanometre trans-electrode membrane. Nature 2010, 467(7312):190-193.
95. Merchant C.A., Healy K., Wanunu M., Ray V., Peterman N., Bartel J., et al. DNA translocation through graphene nanopores. Nano Lett 2010, 10(8):2915-2921.
96. Bayley H. Are we there yet? Comment on "Nanopores: A journey towards DNA sequencing" by Meni Wanunu. Phys Life Rev 2012, 9(2):161-163.
97. Hall A.R., Scott A., Rotem D., Mehta K.K., Bayley H., Dekker C. Hybrid pore formation by directed insertion of [alpha]-haemolysin into solid-state nanopores. Nat Nanotechnol 2010, 5(12):874-877.
98. Bell N.A.W., Engst C.R., Ablay M., Divitini G., Ducati C., Liedl T., et al. DNA origami nanopores. Nano Lett 2011, 12(1):512-517.
99. Huang S., He J., Chang S., Zhang P., Liang F., Li S., et al. Identifying single bases in a DNA oligomer with electron tunnelling. Nature 2010, 5(12):868-873.
100. Virchow R. Reizung und Reizbarkeit. Archiv für pathologische Anatomie und Physiologie und für klinische Medicin 1858, 14. German.
101. Maulitz R.C. Rudolf Virchow, Julius Cohnheim and the program of pathology. Bull Hist Med 1978, 52(2):162-182.
102. Brigati C., Noonan D.M., Albini A., Benelli R. Tumors and inflammatory infiltrates: friends or foes?. Clin Exp Metastasis 2002, 19(3):247-258.
103. Fujiki H. Gist of Dr. Katsusaburo Yamagiwa's papers entitled "Experimental study on the pathogenesis of epithelial tumors" (I to VI reports). Cancer Sci 2014, 105(2):143-149.
104. Hino O. Revisit: Yamagiwa's carcinogenesis. Oncology 2007, 72:1.
105. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
106. Grundmann E. The concept of Julius Cohnheim on tumor formation and metastasis from the viewpoint of new research results. Zentralbl Allg Pathol 1985, 130(4):323-331.
107. Hansemann D. Das Problem der Krebsmalignität 1920, 17:172-191. Zeitschrift fur Krebsforschung, [German]. 10.1007/BF02016738.
108. Boveri T. The origin of malignant tumors-Translated by Marcella Boveri 1929, vol. 1. Williams and Wilkins, Baltimore.
109. Hardy P.A., Zacharias H. Reappraisal of the Hansemann-Boveri hypothesis on the origin of tumors. Cell Biol Int 2005, 29(12):983-992.
110. Hartwell L.H., Weinert T.A. Checkpoints: controls that ensure the order of cell cycle events. Science 1989, 246(4930):629-634.
111. Hartwell L.H., Kastan M.B. Cell cycle control and cancer. Science 1994, 266:1821-1827.
112. Paulovich A.G., Toczyski D.P., Hartwell L.H. When checkpoints fail. Cell 1997, 88(3):315-321.
113. Tunquist B.J., Schwab M.S., Chen L.G., Maller J.L. The spindle checkpoint kinase Bub1 and Cyclin E/Cdk2 both contribute to the establishment of meiotic metaphase arrest by cytostatic factor. Curr Biol 2002, 12(12):1027-1033.
114. Malumbres M. Physiological relevance of cell cycle kinases. Physiol Rev 2011, 91(3):973-1007.
115. Malumbres M., Barbacid M. Cell cycle kinases in cancer. Curr Opin Genet Dev 2007, 17(1):60-65.
116. Lasserre R., Puget E., Vallee M., Borrel A.J. Ultra-virulent embryo-cultures from venereal tumors of the dog. C R Hebd Seances Acad Sci 1951, 232(18):1715-1716.
117. Oberling C. Functional components in virus carcinogenesis. Acta Unio Int Contra Cancrum 1961, 17:171-180.
118. Service P. On an invisible microbe antagonistic toward dysenteric bacilli: brief note by Mr. F. D'Herelle, presented by Mr. Roux. Res Microbiol 2007, 158(7):553-554. Commemoration of Felix Herelle's discovery.
119. nobelprize The Nobel prize in physiology or medicine 1926, Nobelprize.org. http://www.nobelprize.org/nobel_prizes/medicine/laureates/1926/.
120. Petithory J.C., Theodorides J., Brumpt L. A challenged Nobel Prize: Johannes Fibiger, 1926. Hist Sci Med 1997, 31(1):87-95.
121. Stolt C.-M., Klein G., Jansson A.T.R. An analysis of a wrong Nobel Prize Johannes Fibiger, 1926: A study in the Nobel archives. Advances in Cancer Research 2004, 1-12. Academic Press.
122. nobelprize, http://www.nobelprize.org/nobel_prizes/medicine/laureates/2011/press.html Ralph Steinman, 2011, nobelprize.org.
123. Judson H.F. Reflections on the historiography of molecular biology. Minerva 1980, 18(3):369-421.
124. Judson H.F. The eighth day of creation: the makers of the revolution in biology 1996, vol. 1. CSHLP, [Commemorative Edition].
125. Judson H.F. The greatest surprise for everyone notes on the 50th anniversary of the double helix. N Engl J Med 2003, 348(17):1712-1714.
126. Watson J.D., Sixth Daniel C., Baker Memorial Lecture, Induction of cancer by DNA viruses. Ann Otol Rhinol Laryngol 1980, 89(6 Pt 1):489-496.
127. Nowell P.C., Hungerford D.A. A minute chromosome in human chronic granulocytic leukemia. Blut 1960, 132. 1497.
128. Nowell P.C. Discovery of the Philadelphia chromosome: a personal perspective. J Clin Invest 2007, 117(8):2033-2035.
129. Chandra H.S., Heisterkamp N.C., Hungerford A., Morrissette J.J.D., Nowell P.C., Rowley J.D., et al. Philadelphia chromosome symposium: commemoration of the 50th anniversary of the discovery of the Ph chromosome. Cancer Genetics 2011, 204(4):171-179.
130. Rowley J.D. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973, 243:290-293.
131. Heisterkamp N. Localization of the c-ABL oncogene adjacent to a translocation breakpoint in chronic myelocytic leukemia. Nature 1983, 306:239-242.
132. Groffen J. Philadelphia chromosomal breakpoints are clustered within a limited region, BCR, on chromosome 22. Cell 1984, 36:93-99.
133. Chen J., Odenike O., Rowley J.D. Leukaemogenesis: more than mutant genes. Nat Rev Cancer 2010, 10(1):23-36.
134. nobelprize, http://www.nobelprize.org/nobel_prizes/medicine/laureates/1975/Nobel 2 Dulbecco Baltimore & Temin. 1975, nobelorg.
135. Sambrook J., Westphal H., Srinivasan P.R., Dulbecco R. The integrated state of viral DNA in SV40-transformed cells. Proc Natl Acad Sci U S A 1968, 60(4):1288-1295.
136. nobelprize, http://www.nobelprize.org/nobel_prizes/medicine/laureates/1989/press.html Nobel 2 Bishop & Varmus. 1989, nobelorg.
137. Varmus H.E., Vogt P.K., Bishop J.M. Integration of deoxyribonucleic acid specific for Rous sarcoma virus after infection of permissive and nonpermissive hosts. Proc Natl Acad Sci U S A 1973, 70(11):3067-3071.
138. nobelprize, http://www.nobelprize.org/nobel_prizes/medicine/laureates/1966/Nobel 2 Rous and Huggins. 1966, nobelprizeorg.
139. Farber S. Chemotherapy in the treatment of leukemia and wilms tumor. JAMA 1966, 198(8):826-836.
140. Chabner B.A., Roberts T.G. Timeline: chemotherapy and the war on cancer. Nat Rev Cancer 2005, 5:65-72.
141. Zinzi L., Capparelli E., Cantore M., Contino M., Leopoldo M., Colabufo N.A. Small and Innovative Molecules as New Strategy to Revert MDR, Front. 4, 2 eCollection 2014.
142. Luria S.E., Delbruck M. Mutations of bacteria from virus sensitivity to virus resistance. Genetics 1943, 28(6):491-511.
143. Skipper H.E. The forty-year-old mutation theory of Luria and Delbruck and its pertinence to cancer chemotherapy. Adv Cancer Res 1983, 40:331-363.
144. Stehelin D., Varmus H.E., Bishop J.M., Vogt P.K. DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature 1976, 260(5547):170-173.
145. Hayward W.S., Neel B.G., Astrin S.M. Activation of a cellular onc gene by promoter insertion in ALV-induced lymphoid leukosis. Nature 1981, 290(5806):475-480.
146. Varmus H.E., Quintrell N., Ortiz S. Retroviruses as mutagens: insertion and excision of a nontransforming provirus alter expression of a resident transforming provirus. Cell 1981, 25(1):23-36.
147. Santos E., Martin-Zanca D., Reddy E.P., Pierotti M.A., Della Porta G., Barbacid M. Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. Science 1984, 223(4637):661-664.
148. Taparowsky E., Suard Y., Fasano O., Shimizu K., Goldfarb M., Wigler M. Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change. Nature 1982, 300(5894):762-765.
149. Knudson A.G. Two genetic hits(more or less) to cancer. Nat Rev Cancer 2001, 1:157-162.
150. Levine A.J., Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009, 9(10):749-758.
151. Chau B.N., Wang J.Y.J. Coordinated regulation of life and death by RB. Nat Rev Cancer 2003, 3(2):130-138.
152. nobelprize, http://www.nobelprize.org/nobel_prizes/medicine/laureates/2001/Nobel 2 Hartwell Nurse and Hunt. 2001, nobelprizeorg.
153. Hartwell L.H. Nobel Lecture. Yeast and cancer. Biosci Rep 2002, 22(3-4):373-394.
154. Nurse P.M. Nobel Lecture. Cyclin dependent kinases and cell cycle control. Biosci Rep 2002, 22(5-6):487-499.
155. Hunt T. Nobel Lecture. Protein synthesis, proteolysis, and cell cycle transitions. Biosci Rep 2002, 22(5-6):465-486.
156. nobelprize, http://www.nobelprize.org/nobel_prizes/medicine/laureates/2009/Nobel 2 Blackburn Greider Szostack. 2009, nobelprizeorg.
157. Blackburn E.H. Telomeres and telomerase: the means to the end(Nobel Lecture). Angew Chem Int Ed 2010, 49(41):7405-7421.
158. nobelprize, http://www.nobelprize.org/nobel_prizes/medicine/laureates/2002/Nobel 2 Brenner Solston Horwitz. 2002, nobelprizeorg.
159. Brenner S. Nobel lecture. Nature's gift to science. Biosci Rep 2003, 23(5-6):225-237.
160. Folkman J. Angiogenesis. Ann Rev Med 2006, 57(1):1-18.
161. Lander E.S. Nature 2001, 409:860-921.
162. Dulbecco R. A turning point in cancer research: sequencing the human genome. Science 1986, 231(4742):1055-1056.
163. Hahn W.C., Counter C.M., Lundberg A.S., Beijersbergen R.L., Brooks M.W., Weinberg R.A. Creation of human tumour cells with defined genetic elements. Nature 1999, 400(6743):464-468.
164. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
165. Sethi N., Kang Y. Unravelling the complexity of metastasis - molecular understanding and targeted therapies. Nat Rev Cancer 2011, 11(10):735-748.
166. Lees J.A., Weinberg R.A. Tossing monkey wrenches into the clock: new ways of treating cancer. Proc Natl Acad Sci U S A 1999, 96(8):4221-4223.
167. Mendelsohn J. A national cancer clinical trials system for targeted therapies. Sci Transl Med 2011, 3(75). 75cm8.
168. Druker B.J. Imatinib: paradigm or anomaly?. Cell Cycle 2004, 3(71538-4101):831-833.
169. Druker B.J. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008, 112:4808-4817.
170. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996, 2(5):561-566.
171. Daley G.Q., Van Etten R.A., Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990, 247(4944):824-830.
172. Izar B., Rotow J., Gainor J., Clark J., Chabner B. Pharmacokinetics, clinical indications, and resistance mechanisms in molecular targeted therapies in cancer. Pharmacol Rev 2013, 65(4):1351-1395.
173. Wagle N., Emery C., Berger M.F., Davis M.J., Sawyer A., Pochanard P., et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011, 29(22):3085-3096.
174. Davies H., Bignell G., Cox C., Stephens P., Edkins S., Clegg S., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417(6892):949-954.
175. Siegel R., Ward E., Brawley O., Jemal A. Cancer statistics. Cancer J Clin 2011, 61(4):212-236.
176. Queirolo P., Acquati M. Targeted therapies in melanoma. Cancer Treat Rev 2006, 32(7):524-531.
177. Sosman J.A., Kim K.B., Schuchter L., Gonzalez R., Pavlick A.C., Weber J.S., et al. Survival in BRAF V600 "Mutant Advanced Melanoma Treated with Vemurafenib". N Engl J Med 2012, 366(8):707-714.
178. Van Allen E.M., Wagle N., Sucker A., Treacy D.J., Johannessen C.M., Goetz E.M., et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov 2014, 4(1):94-109.
179. Poulikakos P.I., Persaud Y., Janakiraman M., Kong X., Ng C., Moriceau G., et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011, 480(7377):387-390.
180. Molina-Arcas M., Downward J. How to fool a wonder drug: truncate and dimerize. Cancer Cell 2012, 21(1):7-9.
181. Nazarian R., Shi H., Wang Q., Kong X., Koya R.C., Lee H., et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468(7326):973-977.
182. Flaherty K.T. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012, 367:107-114.
183. Association A.L. Lung cancer facts and figures 2015, http://www.lung.org/lung-disease/lung-cancer/resources/facts-figures/lung-cancer-fact-sheet.html.
184. Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007, 7(3):169-181.
185. Sun S., Schiller J.H., Gazdar A.F. Lung cancer in never smokers-a different disease. Nat Rev Cancer 2007, 7(10):778-790.
186. Veale D., Ashcroft T., Marsh C., Gibson G.J., Harris A.L. Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer 1987, 55:513-516.
187. Haeder M. Epidermal growth factor receptor expression in human lung cancer cell lines. Cancer Res 1988, 48:1132-1136.
188. Hirsch F.R. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003, 21:3798-3807.
189. Ohsaki Y. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep 2000, 7:603-607.
190. Ciardiello F., Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008, 358(11):1160-1174.
191. Barker A.J., Gibson K.H., Grundy W., Godfrey A.A., Barlow J.J., Healy M.P., et al. Studies leading to the identification of ZD1839 (Iressa): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 2001, 11(14):1911-1914.
192. Adis I. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415. Drugs R&D 2003, 4(4):243-248.
193. Lynch T.J. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
194. Paez J.G. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
195. Pao W. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004, 101:13306-13311.
196. Han S.W. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005, 23:2493-2501.
197. Mitsudomi T. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005, 23:2513-2520.
198. Pallis A.G., Syrigos K.N. Lung cancer in never smokers: disease characteristics and risk factors. Crit Rev Oncol Hematol 2013, 88(3):494-503.
199. Rosell R., Moran T., Queralt C., Porta R., Cardenal F., Camps C., et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009, 361(10):958-967.
200. Fukuoka M., Wu Y.-L., Thongprasert S., Sunpaweravong P., Leong S.-S., Sriuranpong V., et al. Biomarker analyses and final overall survival results from a Phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011, 29(21):2866-2874.
201. Pham D., Kris M.G., Riely G.J., Sarkaria I.S., McDonough T., Chuai S., et al. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol 2006, 24(11):1700-1704.
202. Yano T., Miura N., Takenaka T., Haro A., Okazaki H., Ohba T., et al. Never-smoking nonsmall cell lung cancer as a separate entity. Cancer 2008, 113(5):1012-1018.
203. Santoro I.L., Ramos R.P., Franceschini J., Jamnik S., Fernandes A.L.G. Non-small cell lung cancer in never smokers: a clinical entity to be identified. Clinics 2011, 66:1873-1877.
204. Couraud S.B., Zalcman G.R., Milleron B., Morin F., Souquet P.-J. Lung cancer in never smokers - a review. Eur J Cancer 2012, 48(9):1299-1311.
205. Cappuzzo F. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol 2005, 23:5007-5018.
206. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non small-cell lung cancer. N Engl J Med 2005, 353(2):123-132.
207. Mok T.S. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
208. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13(3):239-246.
209. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11(2):121-128.
210. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362(25):2380-2388.
211. Zhou C., Wu Y.-L., Chen G., Feng J., Liu X.-Q., Wang C., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12(8):735-742.
212. Gazdar A.F. Personalized medicine and inhibition of EGFR signaling in lung cancer. N Engl J Med 2009, 361(10):1018-1020.
213. Sequist L.V., Waltman B.A., Dias-Santagata D., Digumarthy S., Turke A.B., Fidias P., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 3(75). 75ra26.
214. Gridelli C., de Marinis F., Cappuzzo F., Di Maio M., Hirsch F.R., Mok T., et al. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian association of thoracic oncology. Clin Lung Cancer 2014, 15(3):173-181.
215. Morgensztern D., Campo M.J., Dahlberg S.E., Doebele R.C., Garon E., Gerber D.E., et al. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol 2015, 10(1):S1-S63.
216. Sequist L.V., Yang J.C.-H., Yamamoto N., O'Byrne K., Hirsh V., Mok T., et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013, 31:3327-3334.
217. Joshi M., Rizvi S.M., Belani C.P. Afatinib for the treatment of metastatic non-small cell lung cancer. Cancer 2015, 7:75-82. eCollection 2015. 10.2147/CMAR.S51808.
218. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2(2):127-137.
219. Lenferink A.E.G., Pinkas-Kramarski R., Van De Poll M.L.M., Van Vugt M.J.H., Klapper L.N., Tzahar E., et al. Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J 1998, 17(12):3385-3397.
220. Sebastian M., Chih-Hsin Yang J., Sequist L., Schuler M., Mok T., Yamamoto N., et al. Analysis of overall survival(OS) in two large open-label phase III studies(LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy(CT) in patients(pts) with advanced non-small cell lung cancer(NSCLC) harboring common(Del19/L858R) epidermal growth factor receptor mutations(EGFR mut). Eur Respir J 2014, 44(Suppl. 58).
221. Yang J.C.-H., Wu Y.-L., Schuler M., Sebastian M., Popat S., Yamamoto N., et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2015, 16(2):141-151.
222. Rossi A., Di Maio M. LUX-lung: determining the best EGFR inhibitor in NSCLC?. Lancet Oncol 2015, 16(2):118-119.
223. Chiarle R., Voena C., Ambrogio C., Piva R., Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008, 8(1):11-23.
224. Cappuzzo F., Moro-Sibilot D., Gautschi O., Boleti E., Felip E., Groen H.J.M., et al. Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus. Lung Cancer 2015, 87(2):89-95.
225. Pender A., Popat S. The efficacy of crizotinib in patients with ALK-positive non-small cell lung cancer. Ther Adv Respir Dis 2015, (22). 1753465815577738.
226. Viala M., Brosseau S., Planchard D., Besse B., Soria J.-C. Inhibiteurs de ALK de 2e génération dans le cancer bronchique non àpetites cellules: revue de la littérature. Bull Cancer 2015, 102.
227. Iacono D., Chiari R., Metro G., Bennati C., Bellezza G., Cenci M., et al. Future options for ALK-positive non-small cell lung cancer. Lung Cancer 2015, 87(3):211-219.
228. Soda M. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
229. Rolfo C., Passiglia F., Castiglia M., Raez L.E., Germonpre P., Gil-Bazo I., et al. ALK and crizotinib: after the honeymoon.. . what else? Resistance mechanisms and new therapies to overcome it. Transl Lung Cancer Res 2014, 3(4):250-261.
230. Camidge D.R., Bang Y.-J., Kwak E.L., Iafrate A.J., Varella-Garcia M., Fox S.B., et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012, 13(10):1011-1019.
231. Shaw A.T., Kim D.-W., Nakagawa K., Seto T., Crinó L., Ahn M.-J., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013, 368(25):2385-2394.
232. Camidge D.R., Kono S.A., Lu X., Okuyama S., Barón A.E., Oton A.B., et al. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol 2011, 6:774-780.
233. Sakamoto H., Tsukaguchi T., Hiroshima S., Kodama T., Kobayashi T., Fukami T.A., et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 2011, 19(5):679-690.
234. Seto T., Kiura K., Nishio M., Nakagawa K., Maemondo M., Inoue A., et al. CH5424802 (RO, 802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol 2013, 14(7):590-598. 5424.
235. Reckamp K.L. Future of ALK inhibition in non-small-cell lung cancer. Lancet Oncol 2014, 15(10):1047-1049.
236. Rolfo C., Passiglia F., Russo A., Pauwels P. Looking for a new panacea in ALK-rearranged NSCLC: may be ceritinib?. Expert Opin Ther Targets 2014, 18(9):983-985.
237. Vogelstein B., Papadopoulos N., Velculescu V., Zhou S., Diaz A.J., Kinzler K. Cancer genome landscapes. Science 2013, 339(6127):1546-1558.
238. Sjöblom T., Jones S.N., Wood L.D., Parsons D.W., Lin J., Barber T.D., et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314(5797):268-274.
239. Wood L.D., Parsons D.W., Jones S.N., Lin J., Sjöblom T., Leary R.J., et al. The genomic landscapes of human breast and colorectal cancers. Science 2007, 318(5853):1108-1113.
240. Kaiser J. First pass at cancer genome reveals complex landscape. Science 2006, 313(5792):1370.
241. Network C.G.A.R. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474(7353):609-615.
242. Shah S.P., Roth A., Goya R., Oloumi A., Ha G., Zhao Y., et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012, 486(7403):395-399.
243. Swanton C. Plasma-derived tumor DNA analysis at whole-genome resolution. Clin Chem 2013, 59(1):6-8.
244. Arnedos M., Vielh P., Soria J.-C., Andre F. The genetic complexity of common cancers and the promise of personalized medicine: is there any hope?. J Pathol 2014, 232(2):274-282.
245. Gatenby R. Perspective: finding cancer's first principles. Nature 2012, 491(7425):S55.
246. Gatenby R.A., Gillies R.J., Brown J.S. Of cancer and cave fish. Nat Rev Cancer 2011, 11:237-238.
247. Parsons D.W., Jones S.N., Zhang X., Lin J.C.-H., Leary R.J., Angenendt P., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321(5897):1807-1812.
248. Koppenol W.H., Bounds P.L., Dang C.V. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 2011, 11(5):325-337.
249. nobelprize, http://www.nobelprize.org/nobel_prizes/medicine/laureates/1931/Nobel 2 Warburg, Otto. 1931, nobelprizeorg.
250. Denko N.C. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 2008, 8(9):705-713.
251. Cairns R.A., Harris I.S., Mak T.W. Regulation of cancer cell metabolism. Nat Rev Cancer 2011, 11(2):85-95.
252. Xu W., Yang H., Liu Y., Yang Y., Wang P., Kim S.-H., et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 2011, 19(1):17-30.
253. Sasaki M., Knobbe C.B., Munger J.C., Lind E.F., Brenner D., Brustle A., et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 2012, 488(7413):656-659.
254. Zhao S., Lin Y., Xu W., Jiang W., Zha Z., Wang P., et al. Glioma-derived mutations in IDH1 dominantly inhibit idh1 catalytic activity and Induce HIF-1α. Science 2009, 324(5924):261-265.
255. Dang L., White D.W., Gross S., Bennett B.D., Bittinger M.A., Driggers E.M., et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009, 462(7274):739-744.
256. Cohen A., Holmen S., Colman H. IDH1 and IDH2 mutations in gliomas. Curr Neurol Neurosci Rep 2013, 13:345.
257. Pansuriya T.C., van Eijk R., d'Adamo P., van Ruler M.A.J.H., Kuijjer M.L., Oosting J., et al. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet 2011, 43(12):1256-1261.
258. Lu C., Ward P.S., Kapoor G.S., Rohle D., Turcan S., Abdel-Wahab O., et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012, 483(7390):474-478.
259. Zhao S., Guan K.-L. IDH1 mutant structures reveal a mechanism of dominant inhibition. Cell Res 2010, 20(12):1279-1281.
260. Kalinina J., Carroll A., Wang L., Yu Q., Mancheno D., Wu S., et al. Detection of "oncometabolite" 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma. J Mol Med 2012, 90(10):1161-1171. 10.1007/s00109-012-0888-x.
261. Navis A., Niclou S., Fack F., Stieber D., van Lith S., Verrijp K., et al. Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and alpha-KG. Acta Neuropathol Commun 2013, 1(1):18.
262. Turcan S., Rohle D., Goenka A., Walsh L.A., Fang F., Yilmaz E., et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012, 483(7390):479-483.
263. Laffaire J., Everhard S., Idbaih A., Crinière E., Marie Y., de Reyniès A., et al. Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis. Neuro-oncol 2011, 13(1):84-98.
264. Yan H., Parsons D.W., Jin G., McLendon R., Rasheed B.A., Yuan W., et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009, 360(8):765-773.
265. Labussière M., Idbaih A., Wang X.-W., Marie Y., Boisselier B., Falet C., et al. All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology 2010, 74(23):1886-1890.
266. Watanabe T., Nobusawa S., Kleihues P., Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009, 174(4):1149-1153.
267. SongTao Q., Lei Y., Si G., YanQing D., HuiXia H., XueLin Z., et al. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci 2012, 103(2):269-273.
268. Kranendijk M., Salomons G.S., Gibson K.M., Van Schaftingen E., Jakobs C., Struys E.A. A lymphoblast model for IDH2 gain-of-function activity in d-2-hydroxyglutaric aciduria type II: novel avenues for biochemical and therapeutic studies. Biochim Biophys Acta 2011, 1812(11):1380-1384.
269. Gerardo Valadez J., Grover V.K., Carter M.D., Calcutt M.W., Abiria S.A., Lundberg C.J., et al. Identification of Hedgehog pathway responsive glioblastomas by isocitrate dehydrogenase mutation. Cancer Lett 2013, 328(2):297-306.
270. Walker C.L., Ho S.-m. Developmental reprogramming of cancer susceptibility. Nat Rev Cancer 2012, 12(7):479-486.
271. Minna J.D., Gazdar A.F., Sprang S.R., Herz J. A Bull's eye for targeted lung cancer therapy. Science 2004, 304(5676):1458-1461.
272. Rovigatti U. Is there an infectious agent behind prostate cancer? Advances in Prostate Cancer 2013, vol. 3:19-62. InTech, Wien, 42.
273. Merlo L.M.F., Pepper J.W., Reid B.J., Maley C.C. Cancer as an evolutionary and ecological process. Nat Rev Cancer 2006, 6(12):924-935.
274. Navin N., Hicks J. Future medical applications of single-cell sequencing in cancer. Genome Med 2011, 3(5):31.
275. Durrett R., Foo J., Leder K., Mayberry J., Michor F. Intratumor heterogeneity in evolutionary models of tumor progression. Genetics 2011, 188(2):461-477.
276. Cairns J. Mutation selection and the natural history of cancer. Nature 1975, 255(5505):197-200.
277. Nowell P.C. The clonal evolution of tumor cell populations. Science 1976, 194:23-28.
278. Nowell P.C. Tumor progression: a brief historical perspective. Semin Cancer Biol 2002, 12:261-266.
279. Tsarouha H., Pandis N., Bardi G., Teixeira M.R., Andersen J.A., Heim S. Karyotypic evolution in breast carcinomas with i(1)(q10) and der(1;16)(q10;p10) as the primary chromosome abnormality. Cancer Genet Cytogenet 1999, 113(2):156-161.
280. Sotiriou C., Piccart M.J. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?. Nat Rev Cancer 2007, 7(7):545-553.
281. Russnes H.G., Navin N., Hicks J., Borresen-Dale A.-L. Insight into the heterogeneity of breast cancer through next-generation sequencing. J Clin Invest 2011, 121(10):3810-3818.
282. Vargo-Gogola T., Rosen J.M. Modelling breast cancer: one size does not fit all. Nat Rev Cancer 2007, 7(9):659-672.
283. Santarius T., Shipley J., Brewer D., Stratton M.R., Cooper C.S. A census of amplified and overexpressed human cancer genes. Nat Rev Cancer 2010, 10(1):59-64.
284. Chin K., DeVries S., Fridlyand J., Spellman P.T., Roydasgupta R., Kuo W.-L., et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006, 10(6):529-541.
285. Gruver A.M., Peerwani Z., Tubbs R.R. Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2(HER2) status in breast carcinoma. J Clin Pathol 2010, 63(3):210-219.
286. Moore M., Gasparini R. FISH as an effective diagnostic tool for the management of challenging melanocytic lesions. Diagn Pathol 2011, 6(1):76.
287. Gatenby R.A., Vincent T.L. Application of quantitative models from population biology and evolutionary game theory to tumor therapeutic strategies. Mol Cancer Ther 2003, 2:919-927.
288. Gatenby R.A., Brown J., Vincent T. Lessons from applied ecology: cancer control using an evolutionary double bind. Cancer Res 2009, 69(19):7499-7502.
289. Campbell L.L., Polyak K. Breast tumor heterogeneity: cancer stem cells or clonal evolution?. Cell Cycle 2007, 6:2332-2338.
290. Marusyk A., Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta 2010, 1805:105-117.
291. Greaves M. Darwin and evolutionary tales in leukemia. Hematol Am Soc Hematol Educ Program 2009, (1):3-12.
292. Greaves M. Cancer. The evolutionary legacy 2000, 288. Oxford University Press - OUP.
293. Greaves M. Darwinian medicine: a case for cancer. Nat Rev Cancer 2007, 7(3):213-221.
294. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366(10):883-892.
295. Poste G. Bring on the biomarkers. Nature 2011, 469(7329):156-157.
296. Gerlinger M., Swanton C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer 2010, 103:1139-1143.
297. Yap T.A., Gerlinger M., Futreal P.A., Pusztai L., Swanton C. Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med 2012, 4(127):127ps10.
298. Greaves M. Cancer stem cells: back to Darwin?. Semin Cancer Biol 2010, 20(2):65-70. Getting to the stem of cancer.
299. Anderson K., Lutz C., van Delft F.W., Bateman C.M., Guo Y., Colman S.M., et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011, 469:356-361.
300. Michor F., Polyak K. The origins and implications of intratumor heterogeneity. Cancer Prev Res (Phila) 2010, 3(11):1361-1364.
301. Almendro V., Kim H.J., Cheng Y.-K., Gönen M., Itzkovitz S., Argani P., et al. Genetic and phenotypic diversity in breast tumor metastases. Cancer Res 2014, 74(5):1338-1348.
302. Navin N., Krasnitz A., Rodgers L., Cook K., Meth J., Kendall J., et al. Inferring tumor progression from genomic heterogeneity. Genome Res 2010, 20(1):68-80.
303. Kreso A., O'Brien C.A., van Galen P., Gan O.I., Notta F., Brown A.M.K., et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 2013, 339(6119):543-548.
304. Almendro V., Cheng Y.-K., Randles A., Itzkovitz S., Marusyk A., Ametller E., et al. Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. Cell Reports 2014, 6(3):514-527.
305. Navin N.E. Tumor evolution in response to chemotherapy: phenotype versus genotype. Cell Rep 2014, 6(3):417-419.
306. Greaves M.F., Maia A.T., Wiemels J.L., Ford A.M. Leukemia in twins: lessons in natural history. Blood 2003, 102:2321-2333.
307. Greaves M.F., Wiemels J. Origins of chromosome translocations in childhood leukaemia. Nat Rev Cancer 2003, 3:639-649.
308. Loeb L.A. Human cancers express mutator phenotypes: origin, consequences and targeting. Nat Rev Cancer 2011, 11(6):450-457.
309. Harris J.F., Chambers A.F., Hill R.P., Ling V. Metastatic variants are generated spontaneously at a high rate in mouse KHT tumor. Proc Natl Acad Sci U S A 1982, 79(18):5547-5551.
310. Bodmer W., Loeb L.A. Genetic instability is not a requirement for tumor development. Cancer Res 2008, 68:3558-3561.
311. Tomlinson I., Bodmer W. Selection, the mutation rate and cancer: ensuring that the tail does not wag the dog. Nat Med 1999, 5:11-12.
312. Loeb L.A., Bielas J.H., Beckman R.A., Bodmer I.W. Cancers exhibit a mutator phenotype: clinical implications. Cancer Res 2008, 68:3551-3557.
313. Peto R., Roe F.J., Lee P.N., Levy L., Clack J. Cancer and ageing in mice and men. Br J Cancer 1975, 32(4):411-426.
314. Maley C., Galipeau P., Finley J., Wongsurawat V., Li X., Sanchez C., et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 2006, 38:468-473.
315. Merlo L.M.F., Shah N.A., Li X., Blount P.L., Vaughan T.L., Reid B.J., et al. A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma. Cancer Prev Res 2010, 3(11):1388-1397.
316. Vincent T.L., Gatenby R.A. Modeling cancer as an evolutionary game. Int Game Theory Rev 2005, 7:331-346.
317. Gatenby R.A., Gillies R.J. Why do cancers have high aerobic glycolysis?. Nat Rev Cancer 2004, 4:891-899.
318. Gatenby R.A., Gillies R.J. A microenvironmental model of carcinogenesis. Nat Rev Cancer 2008, 8(1):56-61.
319. Alexandrov L.B., Nik-Zainal S., Wedge D.C., Aparicio S.A.J.R., Behjati S., Biankin A.V., et al. Signatures of mutational processes in human cancer. Nature 2013, 500(7463):415-421.
320. Baca S.C., Prandi D., Lawrence M.S., Mosquera J.M., Romanel A., Drier Y., et al. Punctuated evolution of prostate cancer genomes. Cell 2013, 153(3):666-677.
321. Baslan T., Kendall J., Rodgers L., Cox H., Riggs M., Stepansky A., et al. Genome-wide copy number analysis of single cells. Nat Protoc 2012, 7(6):1024-1041.
322. Potter N.E., Ermini L., Papaemmanuil E., Cazzaniga G., Vijayaraghavan G., Titley I., et al. Single-cell mutational profiling and clonal phylogeny in cancer. Genome Res 2013, 23(12):2115-2125.